Inhibitors of the Myelin-Associated Glycoprotein (mag)

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes new chemical compounds that function as inhibitors of the myelin-associated glycoprotein (MAG), a molecule in the central nervous system that suppresses the regeneration of nerve cells after injury. These novel inhibitors are based on derivatives of neuraminic acid, modified by the addition of various amino acids, and show significantly higher binding affinity to MAG than previous molecules. The compounds can potentially reverse or limit the inhibitory effect of MAG, thus promoting nerve regeneration. The patent also details methods for synthesizing these compounds.

Use CasesContent extracted from patent full text and abstract with AI.

• Development of pharmaceuticals to promote nerve regeneration after spinal cord injuries, such as in the treatment of paralysis or traumatic injuries.
• Treatment of degenerative neurological diseases that involve nerve damage or impaired nerve regeneration, such as multiple sclerosis or amyotrophic lateral sclerosis (ALS).
• Research tools to study neuronal regeneration, MAG signaling, and other molecular processes related to nerve growth.
• Potential therapeutic agents for peripheral nerve damage where MAG inhibition could accelerate repair or improve outcomes.

BenefitsContent extracted from patent full text and abstract with AI.

• May enable and accelerate the regeneration of central nervous system nerves after injury, offering hope for conditions currently considered irreversible, such as spinal cord injuries and paralysis.
• Offers improved potency compared to earlier MAG inhibitors, meaning smaller doses may be effective and side effects minimized.
• Potential to improve the quality of life for patients suffering from nerve injuries, degenerative neurological diseases, or related conditions.
• Provides new chemical tools for neuroscience research, allowing better understanding and manipulation of nerve growth pathways.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to a composition having the general structure (formula), wherein R1 is a hydrophobic group, R2 is hydrogen (H), a cation or an alkyl ester, R3 is hydrogen (H) or a group that can be converted into the hydroxy group under physiological conditions, R4 is a hydrophobic group, R5 is hydrogen (H) or an alkyl group, an amino acid residue or a peptidyl residue, R6 is hydrogen (H), a cation, a hydrolyzable group, an amino acid residue, or a peptide group, and X is an oxygen atom (O) or an NH group. The invention further relates to a method for producing said composition.